Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCT NYSE:ANRO NASDAQ:NMRA NASDAQ:OCGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$2.71-2.2%$3.07$1.05▼$3.97$274.72M1.92630,070 shs668,910 shsANROAlto Neuroscience$3.06-0.3%$2.61$1.60▼$15.04$83.11M1.82118,220 shs220,948 shsNMRANeumora Therapeutics$1.56-20.4%$1.15$0.61▼$17.19$317.03M2.872.20 million shs2.11 million shsOCGNOcugen$0.99-3.5%$1.03$0.52▼$1.40$300.79M3.843.51 million shs4.43 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics-2.34%-17.50%-3.90%+87.54%-18.62%ANROAlto Neuroscience-0.16%-0.65%+31.33%+25.87%-71.68%NMRANeumora Therapeutics-20.41%-33.62%+99.44%+100.98%-87.87%OCGNOcugen-3.53%-8.84%+7.25%+29.88%-29.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADCTADC Therapeutics1.4092 of 5 stars3.51.00.00.00.60.80.6ANROAlto Neuroscience1.8445 of 5 stars3.31.00.00.01.70.81.3NMRANeumora Therapeutics2.4192 of 5 stars3.13.00.00.00.62.51.3OCGNOcugen1.4898 of 5 stars3.52.00.00.02.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 3.00Buy$7.75185.98% UpsideANROAlto Neuroscience 2.57Moderate Buy$8.50177.78% UpsideNMRANeumora Therapeutics 2.22Hold$7.14357.88% UpsideOCGNOcugen 3.00Buy$6.00503.86% UpsideCurrent Analyst Ratings BreakdownLatest ANRO, ADCT, NMRA, and OCGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025NMRANeumora TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$4.00 ➝ $5.006/26/2025ANROAlto NeuroscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/24/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.006/24/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.006/20/2025ADCTADC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$8.00 ➝ $5.006/13/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $10.005/15/2025ADCTADC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.005/15/2025ANROAlto NeuroscienceWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.005/13/2025NMRANeumora TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/12/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.005/12/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$70.84M3.79N/AN/A($2.10) per share-1.29ANROAlto NeuroscienceN/AN/AN/AN/A$5.62 per shareN/ANMRANeumora TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AOCGNOcugen$4.05M71.64N/AN/A$0.10 per share9.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$157.85M-$1.45N/AN/AN/A-197.64%N/A-45.57%8/5/2025 (Estimated)ANROAlto Neuroscience-$61.43M-$2.34N/AN/AN/AN/A-39.35%-33.86%8/12/2025 (Estimated)NMRANeumora Therapeutics-$243.79M-$1.61N/AN/AN/AN/A-84.79%-77.57%8/6/2025 (Estimated)OCGNOcugen-$54.05M-$0.19N/AN/AN/A-1,271.12%-223.00%-92.20%N/ALatest ANRO, ADCT, NMRA, and OCGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ANROAlto Neuroscience-$0.57N/AN/AN/AN/AN/A8/6/2025Q2 2025NMRANeumora Therapeutics-$0.38N/AN/AN/AN/AN/A8/5/2025Q2 2025ADCTADC Therapeutics-$0.36N/AN/AN/A$17.82 millionN/A8/1/2025Q2 2025OCGNOcugen-$0.06-$0.05+$0.01-$0.05$0.35 million$1.37 million5/14/2025Q1 2025ADCTADC Therapeutics-$0.38-$0.36+$0.02-$0.36$17.71 million$23.03 million5/13/2025Q1 2025ANROAlto Neuroscience-$0.59-$0.53+$0.06-$0.56N/AN/A5/12/2025Q1 2025NMRANeumora Therapeutics-$0.40-$0.42-$0.02-$0.42N/AN/A5/9/2025Q1 2025OCGNOcugen-$0.06-$0.05+$0.01-$0.05N/A$1.48 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/AANROAlto NeuroscienceN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.464.16ANROAlto Neuroscience0.1522.5322.53NMRANeumora TherapeuticsN/A8.988.98OCGNOcugen1.742.602.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%ANROAlto NeuroscienceN/ANMRANeumora Therapeutics47.65%OCGNOcugen10.27%Insider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%ANROAlto Neuroscience11.13%NMRANeumora Therapeutics26.80%OCGNOcugen4.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics31099.18 million93.82 millionOptionableANROAlto NeuroscienceN/A27.07 million24.06 millionN/ANMRANeumora Therapeutics108161.75 million118.40 millionOptionableOCGNOcugen80292.03 million279.12 millionOptionableANRO, ADCT, NMRA, and OCGN HeadlinesRecent News About These CompaniesOcugen Inc’s Earnings Call: Progress Amid Financial Challenges1 hour ago | msn.comOcugen Reports Progress in Gene Therapy TrialsAugust 1 at 12:51 AM | tipranks.comOcugen Wins Dismissal of Securities LawsuitAugust 1 at 9:13 PM | theglobeandmail.comOcugen (OCGN) Q2 Revenue Jumps 20%August 1 at 7:16 PM | fool.comOcugen, Inc. (OCGN) Q2 2025 Earnings Call TranscriptAugust 1 at 1:15 PM | seekingalpha.comOcugen (OCGN) Reports Q2 Loss, Misses Revenue EstimatesAugust 1 at 10:35 AM | zacks.comOcugen Provides Business Update with Second Quarter 2025 Financial ResultsAugust 1 at 8:25 AM | globenewswire.comOcugen Q2 2025 Earnings PreviewAugust 1 at 4:19 AM | msn.comGSA Capital Partners LLP Increases Stake in Ocugen, Inc. (NASDAQ:OCGN)July 31 at 3:55 AM | marketbeat.comOcugen (OCGN) to Release Quarterly Earnings on FridayJuly 25, 2025 | marketbeat.comOcugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three YearsJuly 23, 2025 | msn.comOcugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership TeamJuly 21, 2025 | manilatimes.netMOcugen, Inc. Strengthens Retina Scientific Advisory Board and Leadership Team to Advance Gene Therapy Development for Blindness DiseasesJuly 21, 2025 | quiverquant.comQOcugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership TeamJuly 21, 2025 | globenewswire.comOcugen Doses First Patient in Pivotal Trial for Stargardt Gene TherapyJuly 20, 2025 | msn.comOcugen Announces Q2 2025 Financial Results Call and Business UpdateJuly 18, 2025 | msn.comOcugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for ...July 18, 2025 | gurufocus.comOcugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for ...July 18, 2025 | gurufocus.comOcugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt DiseaseJuly 18, 2025 | globenewswire.comOcugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial ResultsJuly 17, 2025 | globenewswire.comOcugen (NASDAQ:OCGN) Shares Down 2.8% - Should You Sell?July 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANRO, ADCT, NMRA, and OCGN Company DescriptionsADC Therapeutics NYSE:ADCT$2.71 -0.06 (-2.17%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$2.87 +0.16 (+6.05%) As of 08/1/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Alto Neuroscience NYSE:ANRO$3.06 -0.01 (-0.33%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$3.06 0.00 (-0.16%) As of 08/1/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.Neumora Therapeutics NASDAQ:NMRA$1.56 -0.40 (-20.41%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.64 +0.09 (+5.45%) As of 08/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.Ocugen NASDAQ:OCGN$0.99 -0.04 (-3.53%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.00 +0.00 (+0.14%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
